1. Inicio
  2. Publicaciones
  3. Frequency and impact of somatic co-occurring mutations on post-transplant outcomes in acute myeloid leukemia: a multicenter registry analysis on behalf of the EBMT ALWP.

Frequency and impact of somatic co-occurring mutations on post-transplant outcomes in acute myeloid leukemia: a multicenter registry analysis on behalf of the EBMT ALWP.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Bazarbachi A
  • Galimard JE
  • Abou Dalle I
  • Labopin M
  • Huang H
  • Mayer J
  • Solano C
  • Lioure B
  • Griskevicius L
  • Maertens J
  • Itälä-Remes M
  • Kaare A
  • Gallego-Hernanz MP
  • Bug G
  • Ribera JM
  • Gadisseur A
  • Schmid C
  • Kwon M
  • Poiré X
  • Coccia P
  • Jurado Chacón M
  • Baron F
  • Craddock C
  • Brissot E
  • Nagler A
  • Ciceri F
  • Mohty M

Grupos

Abstract

Acute myeloid leukemia (AML) includes genetically defined subsets. In allogeneic hematopoietic cell transplantation (allo-HCT), the frequency and prognosis of gene-gene interactions may differ from those of patients treated with chemotherapy alone. In this study, adult patients (N = 952) with AML allografted between 2015 and 2023, with available next generation sequencing (NGS) at diagnosis were included. Most frequent mutations were DNMT3A (24%), FLT3-ITD (21%), NPM1 (21%), RUNX1 (16%), NRAS (16%), TET2 (14%), and IDH2 (12%). Multiple correspondence analysis identified distinct groups of co-occurring mutations. Outcome analysis was performed on 646 AML patients allografted in first complete remission (CR1). Six non-overlapping groups were constructed: 1) TP53 mutation (N = 47); 2) NPM1 mutation (N = 129); 3) FLT3-ITD and/or DNMT3A mutation (N = 128); 4) SRSF2 and/or ASXL1 and/or RUNX1 mutation (SAR group) (N = 132); 5) IDH1 and/or IDH2 and/or TET2 mutation (N = 43); and 6) all ten genes unmutated (N = 167). In multivariable analysis, TP53 mutation, adverse karyotype, and age negatively affected leukemia-free survival (LFS) and overall survival (OS). OS was additionally negatively affected when the ten genes were unmutated. Notably, outcomes were excellent for SAR mutations (2-year LFS 76%, OS 84%), indicating allo-HCT in CR1 can overcome their adverse risk at diagnosis.

© 2025. The Author(s), under exclusive licence to Springer Nature Limited.

Datos de la publicación

ISSN/ISSNe:
0268-3369, 1476-5365

BONE MARROW TRANSPLANTATION  SPRINGERNATURE

Tipo:
Article
Páginas:
282-293
PubMed:
41345260
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
0,998 SCImago ℠
Cuartil:
Q2 SCImago ℠

Citas Recibidas en Web of Science: 1

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Adolescent; Adult; Aged; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nucleophosmin; Registries; Young Adult; ASXL1 protein; BCOR protein; biologic factors and agents acting on the immune system; busulfan; CD135 antigen; CEBPA protein; cyclophosphamide; DNA methyltransferase 3A; isocitrate dehydrogenase 1; isocitrate dehydrogenase 2; nucleophosmin; protein tyrosine phosphatase SHP 2; SRSF2 protein; STAG2 protein; TET2 protein; unclassified drug; NPM1 protein, human; nucleophosmin; acute myeloid leukemia; adult; aged; allogeneic hematopoietic stem cell transplantation; Article; blood analysis; bone marrow biopsy; cancer prognosis; cancer specific survival; cancer survival; chi square test; clinical assessment; cohort analysis; comorbidity assessment; complete remission; controlled study; cytogenetics; Cytomegalovirus; data base; disease registry; educed intensity conditioning; European Society for Blood and Marrow Transp

Cita

Compartir